ATN-161
ATN-161 is a novel integrin α5β1 antagonist, which inhibits angiogenesis and growth of liver metastases in a murine model.
Product Specifications
CAS Number
262438-43-7
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Integrin
Type
Reference compound
Related Pathways
Cytoskeleton
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/atn-161.html
Purity
99.36
Solubility
DMSO : 25 mg/mL (ultrasonic) |H2O : 10 mg/mL
Smiles
O=C(N)C[C@@H](C(N)=O)NC([C@H](CS)NC([C@H](CO)NC([C@H](CC1=CNC=N1)NC([C@H]2N(C(C)=O)CCC2)=O)=O)=O)=O
Molecular Formula
C23H35N9O8S
Molecular Weight
597.64
Precautions
H302, H315, H319, H335
References & Citations
[1]Stoeltzing O, et al. Inhibition of integrin alpha5beta1 function with a small peptide (ATN-161) plus continuous 5-FU infusion reduces colorectal liver metastases and improves survival in mice. Int J Cancer. 2003 Apr 20;104 (4) :496-503.|[2]Wang W, et al. The antiangiogenic effects of integrin alpha5beta1 inhibitor (ATN-161) in vitro and in vivo. Invest Ophthalmol Vis Sci. 2011 Sep 14;52 (10) :7213-20.
Shipping Conditions
Blue Ice
Storage Conditions
-80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)
Scientific Category
Reference compound1
Clinical Information
Phase 2
Citation 01
ACS Nano. 2025 Jun 10;19 (22) :20564-20577.|Cancer Cell. 2019 Jan 14;35 (1) :64-80.e7. |J Adv Res. 2025 May 25:S2090-1232 (25) 00370-4.|Sci Signal. 2022 Dec 6;15 (763) :eabn2743.|ACS Biomater Sci Eng. 2023 May 8;9 (5) :2524-2533.|Cell Prolif. 2021 Apr;54 (4) :e13012.|Colloids Surf B Biointerfaces. 2022 Feb:210:112227.|Stem Cell Res Ther. 2022 Jul 18;13 (1) :327.
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
MBS1234130-01 0.02 mg (E-Coli)
Recombinant Burkholderia cenocepacia Biotin synthase (bioB)
Sign In for Pricing
View Details MBS1234130-02 0.02 mg (Yeast)
Recombinant Burkholderia cenocepacia Biotin synthase (bioB)
Sign In for Pricing
View Details